Drugs / ALUTARD SQ Felis domesticus
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06960382 Comparator | Aug 2025 → May 2027 expected | allergic asthma, allergic rhinitis | University of Zurich | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALUTARD SQ Felis domesticus | “"ALUTARD SQ Felis domesticus" is administered intralymphatically.” NCT06960382 ↗ |
| Route | Other | “administered by injection into an inguinal lymph node” NCT06960382 ↗ |